Deep learning-guided discovery of an antibiotic targeting Acinetobacter baumannii.
Gary LiuDenise B CatacutanKhushi RathodKyle SwansonWengong JinJody C MohammedAnush Chiappino-PepeSaad A SyedMeghan FragisKenneth RachwalskiJakob MagolanMichael G SuretteBrian K CoombesTommi S JaakkolaRegina BarzilayJames J CollinsJonathan M StokesPublished in: Nature chemical biology (2023)
Acinetobacter baumannii is a nosocomial Gram-negative pathogen that often displays multidrug resistance. Discovering new antibiotics against A. baumannii has proven challenging through conventional screening approaches. Fortunately, machine learning methods allow for the rapid exploration of chemical space, increasing the probability of discovering new antibacterial molecules. Here we screened ~7,500 molecules for those that inhibited the growth of A. baumannii in vitro. We trained a neural network with this growth inhibition dataset and performed in silico predictions for structurally new molecules with activity against A. baumannii. Through this approach, we discovered abaucin, an antibacterial compound with narrow-spectrum activity against A. baumannii. Further investigations revealed that abaucin perturbs lipoprotein trafficking through a mechanism involving LolE. Moreover, abaucin could control an A. baumannii infection in a mouse wound model. This work highlights the utility of machine learning in antibiotic discovery and describes a promising lead with targeted activity against a challenging Gram-negative pathogen.
Keyphrases
- multidrug resistant
- acinetobacter baumannii
- gram negative
- drug resistant
- machine learning
- deep learning
- klebsiella pneumoniae
- neural network
- pseudomonas aeruginosa
- small molecule
- artificial intelligence
- high throughput
- cancer therapy
- candida albicans
- silver nanoparticles
- single cell
- cystic fibrosis
- anti inflammatory
- body composition
- wound healing
- escherichia coli